A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque.
We created a hybrid adeno-associated virus (AAV) from two related rhesus macaque isolates, called AAVrh32.33, and evaluated it as a vaccine carrier for human immunodeficiency virus type 1 (HIV-1) and type A influenza virus antigens. The goal was to overcome the limitations of vaccines based on other AAVs, which generate dysfunctional T-cell responses and are inhibited by antibodies found in human sera. Injection of a Gag-expressing AAVrh32.33 vector into mice resulted in a high-quality CD8(+) T-cell response. The resulting Gag-specific T cells express multiple cytokines at high levels, including interleukin-2, with many having memory phenotypes; a subsequent boost with an adenovirus vector yielded a brisk expansion of Gag-specific T cells. A priming dose of AAVrh32.33 led to high levels of Gag antibodies, which exceed levels found after injection of adenovirus vectors. Importantly, passive transfer of pooled human immunoglobulin into mice does not interfere with the efficacy of AAVrh32.33 expressing nucleoproteins from influenza virus, as measured by protection to a lethal dose of influenza virus, which is consistent with the very low seroprevalence to this virus in humans. Studies of macaques with vectors expressing gp140 from HIV-1 (i.e., with AAVrh32.33 as the prime and simian adenovirus type 24 as the boost) demonstrated results similar to those for mice with high-level and high-quality CD8(+) T-cell responses to gp140 and high-titered neutralizing antibodies to homologous HIV-1. The biology of this novel AAV hybrid suggests that it should be a preferred genetic vaccine carrier, capable of generating robust T- and B-cell responses.
Lin
Jianping
J
Department of Pathology and Laboratory Medicine, Division of Transfusion Medicine, University of Pennsylvania, TRL Suite 2000, 125 South 31st Street, Philadelphia, PA 19104, USA.
Calcedo
Roberto
R
Vandenberghe
Luk H
LH
Bell
Peter
P
Somanathan
Suryanarayan
S
Wilson
James M
JM
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D000229:Dependovirus / Q000235:genetics*; D015497:HIV-1 / Q000276:immunology; D006801:Humans; D007156:Immunologic Memory; D007252:Influenza Vaccines / Q000276:immunology*; D007371:Interferon-gamma / Q000096:biosynthesis; D008253:Macaca mulatta / Q000821:virology*; D051379:Mice; D008807:Mice, Inbred BALB C; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D016915:AIDS Vaccines; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic; D007371:Interferon-gamma